Gritstone bio is developing immunotherapies for cancer and infectious diseases. Immunotherapies work by activating the patient's immune response - for instance, activating T cells to detect and eliminate cancerous or infected cells. Gritstone is creating a diverse portfolio of immunotherapies using their EDGE platform, an AI-driven platform that can identify T cell targets on tumor or virally infected cells. Gritstone then uses their immunogenic vaccine platform to stimulate the immune system and drive generation of T cells and antibodies against the identified targets. Their portfolio includes two key classes of products. Individualized products that are unique to an individual patient and ‘off-the-shelf’ products that target cancer mutations that recur between different cancer patients. Gritstone is also working on a COVID-19 vaccine to provide longer, more robust immunity to emerging variants.